How MOTS-C Affects Fasting Insulin

MOTS-C should lower fasting insulin by reducing the demand placed on the pancreas:

1. AMPK-driven glucose uptake: By moving GLUT4 to the muscle membrane independently of insulin, MOTS-C allows glucose to leave the bloodstream without the pancreas secreting as much insulin to achieve the same clearance.
2. Improved insulin sensitivity at the tissue level: In high-fat-diet mice, MOTS-C restored insulin-stimulated glucose disposal and reduced compensatory hyperinsulinemia (Lee et al., 2015; Kim et al., 2019).
3. Reduced lipotoxic interference: MOTS-C remodels plasma lipids toward a less insulin-resistant pattern in animal models, easing the free-fatty-acid pressure that drives muscle insulin resistance.

Because fasting insulin rises before fasting glucose in the natural history of insulin resistance, it is the earliest and most sensitive marker of any metabolic benefit.

Evidence caveat: mouse efficacy plus human correlation. No completed interventional trial of native MOTS-C has reported fasting insulin in healthy athletes.

Observational human signal:

• In obese children and adolescents, lower circulating MOTS-C correlated inversely with fasting insulin and HOMA-IR (Du et al., 2018)
• The relationship is not perfectly clean: a 2025 adult cohort found MOTS-C positively correlated with HOMA-IR, interpreted as compensatory upregulation as insulin resistance worsens (Ozkaya et al., 2025)

Plausible direction if the animal data translates:

• Fasting insulin: gradual reduction over weeks
• HOMA-IR: the composite endpoint most likely to move, calculated as (fasting glucose mmol/L x fasting insulin mU/L) / 22.5

Reference ranges for context: HOMA-IR below 1.9 is normal, 2.0-2.9 is early insulin resistance, and above 3.0 is the range worth acting on. A high-dose MK-677 bulk routinely pushes athletes above 3.0, which is the scenario where MOTS-C is most often considered.

Baseline: fasting insulin alongside fasting glucose, drawn in a true 10-12 hour fasted state. Calculate HOMA-IR from the pair.

During use: fasting insulin at week 4, week 8, and week 12, each time paired with glucose so HOMA-IR can be recalculated.

The primary endpoint: judge MOTS-C on the HOMA-IR trend. A reduction of 15% or more from baseline, or a move back toward 2.0 if you started elevated, is a positive efficacy signal. A flat or rising HOMA-IR with no confounder suggests the peptide is not doing much at your dose.

Lab consistency matters: fasting insulin assays vary between labs. Use the same lab across the protocol so your trend is not muddied by assay differences.

Use HOMA-IR as your decision marker: it is the single most useful number for anyone running GH secretagogues, and it turns two cheap routine values into an early-warning system.

If insulin and HOMA-IR fall: that is the result MOTS-C is supposed to produce. Confirm it persists by retesting four weeks after the cycle ends.

If they do not move: do not escalate the dose blindly. Reassess the stack (MK-677, GH, and a carbohydrate surplus all push insulin up) and consider better-evidenced sensitisers like metformin or berberine.

Do not rely on MOTS-C to rescue an aggressive GH-secretagogue protocol: the mechanism is complementary on paper, but no human co-administration data exists.